Menu
Menu
Menu
Menu
Background: Neonatal hypothermia is an important challenge associated with morbidity and mortality. Preventing neonatal hypothermia is important in high-resource countries, but is of fundamental importance in low-resource settings where supportive care is limited. Kangaroo mother care (KMC) is a low-cost intervention that, whenever possible, is strongly recommended for temperature maintenance. During KMC, the World Health Organization (WHO) guidelines recommend the use of a cap/hat, but its effect on temperature control during KMC remains to be established. In the hospitals participating in the projects of the non-governmental organization CUAMM, KMC represents a standard of care, but the heads of the babies often remain uncovered due to local habits or to the unavailability of a cap. The aim of the present study will be to assess the effectiveness and safety of using a woolen cap in maintaining normothermia in low-birth-weight infants (LBWI) during KMC. Methods/design: This is a multicenter (three hospitals), multicountry (three countries), prospective, unblinded, randomized controlled trial of KMC treatment with and without a woolen cap in LBWI. After obtaining parental consent, all infants with a birth weight below 2500g and who are candidates for KMC, based on the clinical decision of the attending physician, will be assigned to the KMC with a woolen cap group or to the KMC without a woolen cap group in a 1:1 ratio according to a computer-generated, randomized sequence. The duration of the study will be until the patient’s discharge, with a maximum treatment duration of 7days. The primary outcome measure will be whether the infants’ temperatures remain within the normal range (36.5-37.5°C) in the course of KMC during the intervention. In all participants, axillary temperature will be measured with a digital thermometer four times per day. In addition, maternal and room temperature will be recorded. Secondary outcome measures will be: episodes of apnea; sepsis; mortality before hospital discharge in-hospital growth; and age at discharge. Discussion: The findings of this study will be important for other units/settings in high- as well low-resource countries where KMC is routinely performed. Based on the results of the present study, we could speculate whether the use of a woolen cap may help to maintain the neonate within the normal thermal range. Furthermore, potential complications such as hyperthermia will be strictly monitored and collected. Trial registration: ClinicalTrials.gov Identifier: NCT02645526(registered on 31 December 2015).
This is a multicenter, prospective, unblinded, randomized clinical trial of KMC treatment with and without a woolen cap in LBWI. The study will be conducted at three hospitals that have three different levels of healthcare in three African countries where Doctors with Africa CUAMM has ongoing projects on maternal-neonatal health. They are: Infants satisfying the following inclusion criteria will be eligible to participate in the study: After obtaining parental consent, all infants with a birth weight below 2500 g and who are candidates for KMC, based on the clinical decision of the attending physician, will be assigned to the KMC with a woolen cap group (KMC + cap) or to the KMC without a woolen cap group (KMC group). All the caps used for the study are handmade by a group of volunteers in Padova. The material (wool) was provided by CUAMM and sizes were standardized. The procedure of initiating, maintaining and stopping the KMC will be based on WHO guidelines [5]. Mothers will be trained in monitoring the baby’s condition and in recognizing dangerous clinical signs during KMC [5]. The duration of the study will be until the patient’s discharge, with a maximum treatment duration of 7 days. In case of documented neonatal hypothermia (temperature below 36.5 °C) or hyperthermia (temperature above 37.5 °C) during the course of the study, the pre-warmed blanket will be added or removed. In case of maternal hyperthermia, we will ask the woman to wear lighter clothes. In these cases, neonatal and maternal temperatures will be measured every hour until the normal range is reached. The primary outcome measure will be whether the infants’ temperatures remain within the normal range (36.5–37.5 °C) in the course of KMC during the intervention. In all participants, axillary temperature will be measured with a digital thermometer (C202; Terumo, Tokyo, Japan) every 6 hours during KMC treatment. Maternal and room temperature will be registered at the same time. Room temperature will be measured at the same times (every 6 hours) by using the same wall thermometers (Oregon Scientific RMR262) in all three study sites. The findings of this study will be important for other units/settings in high- as well low-resource countries where KMC is routinely performed. Based on the results of the present study, we could speculate whether the use of a woolen cap may help to maintain the neonate within the normal thermal range. Furthermore, potential complications such as hyperthermia will be strictly monitored and collected. The lack of information about this topic (temperature during KMC in the specific scenario of head covering) prevented us from obtaining a mathematical estimation of the sample size. Thus, the sample size was arbitrarily defined in order to take into account the enrollment rate of each hospital. According to the number of admissions in each participating hospital, we decided to enroll a total of 300 subjects (150 in the cap group and 150 in the uncovered head group) as follows: 150 at Central Beira Hospital, 90 at St. Luke Wolisso Hospital and 60 at Aber Hospital. Written and oral information will be offered to parents by the attending nurse or physician prior to starting KMC treatment. Informed written consent will be signed by a parent. A senior investigator will be available at all times to discuss concerns raised by parents or clinicians during the course of the trial. Eligible infants will be assigned to the KMC + cap or the KMC group in a 1:1 ratio according to a computer-generated, randomized sequence for each participating hospital. The randomized allocation will be concealed in double-enclosed, opaque, sealed, and sequentially numbered envelopes prepared at the University Hospital of Padua. In the KMC room, the next sequential randomization envelope will be opened only when the attending operator considers the infant to be eligible. The assigned procedure (KMC + cap or KMC group) will be then performed. Cross-over will not be allowed. Analysis will be done as per intention-to-treat. A flow diagram of patient randomization is reported in Fig. 1. Flow diagram of patient randomization Due to the characteristics of the intervention, neither caregivers nor outcome assessors will be masked to treatment allocation. However, the statistician who will perform data analysis will be blind to treatment allocation. To minimize bias, strict criteria and definitions will be maintained during the trial. Before starting the study, all those involved in the study will participate in a meeting where all the details of the study will be presented. Midwives and nurses who are responsible of the maternal and neonatal management during KMC treatment will be educated on the temperature measurements in terms of correct modality (axillary), time of the study, and data collection. Neonatal, maternal and room temperature will be collected four times/day (6.00 am, 12.00 am, 6.00 pm, and 12.00 pm). Data will be recorded in a data sheet designed for this study. All data will be collected by an observer who is not involved in the care of the neonates. The following clinical information will be registered: eligibility, antenatal history, randomization, all data above listed in the ‘Primary outcome measure’ and ‘Secondary outcome measures’ sections. Further information will be collected on expected serious adverse events (SAEs). Personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial by the local principal investigator (PI) in a personal password-protected PC. The PI and the members of the Steering Committee located in Padua will have access to the final trial dataset. Analysis will be performed as per intention-to-treat. Continuous data will be expressed as mean and standard deviation (SD) or median and interquartile range (IQR). The effect of the treatment on primary outcome will be assessed using a Poisson model adjusting for hospital and a set of clinically relevant confounders (maternal temperature, environmental temperature, birth weight, postnatal age). The logarithm of the number of measurements during hospital stay will be used as an offset, in order to take into account the different lengths of hospital stay of each participant. The effect of the treatment on the number of episodes of apnea will be assessed using a Poisson model adjusting for hospital and a set of clinically relevant confounders (neonatal and maternal temperatures, environmental temperature, birth weight, postnatal age). The logarithm of the number of measurements during hospital stay will be used as an offset. The effect of the treatment on binary secondary outcome (sepsis and mortality before hospital discharge) will be assessed using a logistic regression model adjusting for hospital and birth weight. The effect of the treatment on continuous secondary outcome (in-hospital growth) will be assessed using a regression model adjusting for hospital. Statistical analysis will be performed using R 3.2.2 software (R Foundation for Statistical Computing, Vienna, Austria) [11]. A p value less than 0.05 will be considered statistically significant. In this study, 300 infants will be recruited. The trial will terminate when the last recruited infant is discharged from hospital, or dies. Based on a recent study conducted by our group at the Central Hospital of Beira, Mozambique, we consider that we will perform the study in about 14 months (Table 1). Duration of the study The study will be conducted – simultaneously – at the three participating hospitals. Written parental consent is necessary before enrollment of the patients in the study. We consider that there will be no risks for either study group (patients treated with or without a woolen cap). Hypothermic as well as hyperthermic episodes will be strictly monitored in both groups. The study was approved by the Ethics Committees for Human Investigation of the three participating hospitals. At the Central Hospital of Beira the study was approved by the Comitè Nacional di Bioetica para a Saude, Ministerio da Saude (REF: 348/CNBS/15: IRB00002657; Maputo, Mozambique; 8 December 2015); at St. Luke Wolisso Hospital the study was approved by the Lacor Hospital Institutional Research and Ethics Committee (REF: LHIREC N.: 016/03/15; Gulu, Uganda; 30 May 2015); at Aber Hospital the study was approved by the Oromia Regional Health Research Ethical Review Committee Bureau (REF: BEFOABTFH 3657/1-8; Addis Ababa, Ethiopia; 24 June 2015). Compliance will be defined as full adherence to protocol. Compliance with the protocol will be ensured by some members of the project (DM, TS, SM, WM) who are responsible for local data collection. They will monitor adherence to the study protocol weekly and will input the patients’ data in an Excel data sheet. Double data entry will be performed by two independent members at each center to promote data quality. Investigators and study staff will be trained on the importance of completion of the study period of enrolled patients. Parents will also be informed about this crucial aspect to reduce dropout, and a local investigator will be available at each site any time that the parents may need further information or clarification during the study period. Safety measures will include incidence, severity and causality of reported SAEs, represented by changes in occurrence of the expected common neonatal complications and the development of unexpected SAEs. SAE will be defined as unexpected death, apnea not responding to vigorous stimulation, severe hyperthermia (temperature >39 °C) and hypothermia (temperature <35 °C). All SAEs will be followed until complete resolution or until the clinician responsible for the care of the recruited patient considers the event to be chronic or the infant to be stable. A monitoring board, including an independent assessor (not involved in the study) from the University of Padova and assessors from each participating hospital, will review all the deaths and adverse events. If there is a reasonable suspected causal relationship with the intervention, SAEs will be reported to the Ethics Committee to guarantee the safety of the participants. An interim analysis will be performed on the primary endpoint and on SAEs from the first 100 enrolled infants. The interim analysis will be performed by the statistician, who is blinded for the treatment allocation and who will report to the PI. The PI will discuss the results of the interim analysis with the monitoring board and the trial will be ended in case of harm. Criteria for stopping for harm include: a statistically significant difference in the primary outcome between the treatment groups; and a reasonable suspected causal relationship between the intervention and SAEs. Only the local PI will have access to the Excel database with an assigned personal account and password. Subjects will be identified by sex, birth date, and assigned trial number, during and after the trial, in accordance with personal data protection law. The PIs of each site will have complete access to the final trial dataset, and no contractual agreement exists to limit such access for the investigators. The results of the trial are expected to be published in a scientific journal and presented at medical seminars and conferences. The final reporting will follow the Consolidated Standards of Reporting Trials (CONSORT) Statement guidelines (http://www.consort-statement.org).
N/A
